2022 (ongoing) Pfizer, Paris – Head of scientific relationships and partnerships in uro-oncology and breast cancer
Medico-marketing position focused on medical education, KOL relationship, congress strategy, and tactics, partnerships with scientific societies and publishers, and budget management:
- KOL management including oncologists, urologists, and scientific societies
- Developed congress strategy and tactics, managing invitations for 14 breast cancer and 10 uro-oncology congresses. I also organized 6 symposia in 2022, collaborating with experts on scientific programs, reviewing presentations, and providing support on the day of the event. This resulted in positive feedback from clients and an average of over 200 participants in most of our oral interventions.
- Institutional support to publishers to cover our most important communications on key congresses such as the coverage of TALAPRO-2 at ASCO GU 2023 with a group of KOLs writers, a daily e-journal, a summary slideshow, and an expert debate
- Ad boards with scientific societies and KOLs to test and share our key messages and tactics, better understand our care pathway and roles of new clients, and new competitive landscape (prostate)
- Organization of 2 national Pfizer standalone for HCPs, such as « AVENIR » in bladder cancer
2019-2020 (2 years),
Novartis Oncology, Rueil-Malmaison, France - Melanoma Product Manager
- Led the development of an omnichannel marketing strategy in collaboration with experts, dermatologists, patient advocacy groups, and internal teams. This included creating a website for onco-dermatologists with access to scientific news through peer-written articles
- In charge of the marketing strategy and tactics including developing the communication campaign (product, environment, and care pathway), creating communication tools, and conducting ad boards
- Led the sales representatives’ training including the organization of 3 seminars per year
- Led marketing consultants’ relationships and partnerships with the French Society of Dermatology
- Organization of Novartis participation in the most important French congress in onco-dermatology (JDP)
2018 (6 months), Pierre Fabre Laboratories, Boulogne Billancourt, France - Global business developer licensing and M&A
- Acquisition of Neratinib’s market license; Due diligence including scientific, economic, and financial evaluations; Market study on M&A trends and built a strategic analysis report on Puma Biotechnology